Download PDF
Thromb Haemost 2012; 108(02): 357-366
DOI: 10.1160/TH11-12-0868
Endothelium and Vascular Development
Schattauer GmbH

The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration

Marina Poettler
1   Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center Vienna, Medical University Vienna, Austria
,
Matthias Unseld
1   Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center Vienna, Medical University Vienna, Austria
,
Judit Mihaly-Bison
2   Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna, Austria
,
Pavel Uhrin
2   Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna, Austria
,
Florian Koban
2   Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna, Austria
,
Bernd R. Binder   *
2   Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna, Austria
,
Christoph C. Zielinski
1   Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center Vienna, Medical University Vienna, Austria
,
Gerald W. Prager
1   Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center Vienna, Medical University Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received: 16 December 2011

Accepted after major revision: 17 May 2012

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

Summary

Angiogenesis, the sprouting of blood vessels form pre-existing vasculature after injury or in neoplastic diseases, is initiated by growth factor-induced endothelial cell migration. Recently, the major angiogenic growth factor VEGF165 has become the target of therapeutic interventions. However, this approach has been clinically proven to be of limited efficacy, which might be due to the fact that tumour angiogenesis is not only induced by VEGF, but also by a variety of other growth factors. Thus, the identification of a common downstream mediator of growth-factor-induced endothelial cell migration is mandatory to effectively interfere with (tumour-) angiogenesis. We found that the urokinase-type plas-minogen activator (uPA)-system, which affects proteolytic as well as adhesive capacities, represents an essential regulatory mechanism in growth factor-induced endothelial cell migration and invasion. This mechanism was not limited to VEGF165, but mediated pro-angiogenic endothelial cell behaviour induced by various growth factors. Thus, VEGF165, VEGF-E, FGF-2, EGF as well as HGF induced a PI3k-dependent activation of pro-uPA when bound to uPAR, which led to an increase in cell surface fibrinolytic activity. As a consequence, uPAR became internalised and redistributed via LDLR-proteins. Interference with these events led to a reduced migratory response of endothelial cells towards VEGF in vitro as well as endothelial cell invasion in vivo. These data give first evidence that the uPA-system, which represents the only level-of-evidence-1 cancer biomarker system for prognosis and/or prediction in node negative breast cancer, might directly affect (tumour-) angiogenesis.

Keywords

uPA/plasminogen system - angiogenesis - endothelial cells - growth factors

* Deceased August 28th, 2010.


 

  • References

  • 1 Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 06: 389-395.
    CrossrefPubMedGoogle Scholar
  • 2 Schmidt-Erfurth UE. et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118: 831-839.
    CrossrefPubMedGoogle Scholar
  • 3 Gerger A. et al. Molecular predictors of response to antiangiogenesis therapies. Cancer J 2011; 17: 134-141.
    CrossrefPubMedGoogle Scholar
  • 4 Fischer C. et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer 2008; 08: 942-956.
    CrossrefPubMedGoogle Scholar
  • 5 Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
    CrossrefPubMedGoogle Scholar
  • 6 Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
    CrossrefPubMedGoogle Scholar
  • 7 Prager GW. et al. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004; 103: 955-962.
    PubMedGoogle Scholar
  • 8 Prager GW. et al. Vascular Endothelial Growth Factor Receptor-2-Induced Initial Endothelial Cell Migration Depends on the Presence of the Urokinase Receptor. Circ Res 2004; 94: 1562-1570.
    CrossrefPubMedGoogle Scholar
  • 9 Nykjaer A. et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16: 2610-2620.
    CrossrefPubMedGoogle Scholar
  • 10 Tarui T. et al. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 2001; 276: 3983-3990.
    CrossrefPubMedGoogle Scholar
  • 11 Wei Y. et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
    CrossrefPubMedGoogle Scholar
  • 12 Felsenfeld DP. et al. Ligand binding regulates the directed movement of beta1 integrins on fibroblasts. Nature 1996; 383: 438-440.
    CrossrefPubMedGoogle Scholar
  • 13 Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996; 84: 359-369.
    CrossrefPubMedGoogle Scholar
  • 14 Lawson MA, Maxfield FR. Ca(2+)- and calcineurin-dependent recycling of an integrin to the front of migrating neutrophils. Nature 1995; 377: 75-79.
    CrossrefPubMedGoogle Scholar
  • 15 Schwarz HP. et al. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 2000; 95: 1703-1708.
    PubMedGoogle Scholar
  • 16 Mechtcheriakova D. et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001; 15: 230-242.
    CrossrefPubMedGoogle Scholar
  • 17 Huber J. et al. The Isoprostane 8-iso-PGE(2) Stimulates Endothelial Cells to Bind Monocytes via Cyclic AMP- and p38 MAP Kinase-Dependent Signaling Pathways. Antioxid Redox Signal 2003; 05: 163-169.
    CrossrefPubMedGoogle Scholar
  • 18 Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.
    CrossrefPubMedGoogle Scholar
  • 19 Mochizuki Y. et al. Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase. Oncogene 2002; 21: 7027-7033.
    CrossrefPubMedGoogle Scholar
  • 20 Zubilewicz A. et al. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene 2001; 20: 1403-1413.
    CrossrefPubMedGoogle Scholar
  • 21 Karsan A. et al. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol 1997; 151: 1775-1784.
    PubMedGoogle Scholar
  • 22 Matsumoto T. et al. p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 2002; 156: 149-160.
    CrossrefPubMedGoogle Scholar
  • 23 Hirata A. et al. Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer Sci 2004; 95: 614-618.
    CrossrefPubMedGoogle Scholar
  • 24 Sengupta S. et al. Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation 2003; 107: 2955-2961.
    CrossrefPubMedGoogle Scholar
  • 25 Goldman E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 1907; 02: 1236-1240.
    PubMedGoogle Scholar
  • 26 Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
    CrossrefPubMedGoogle Scholar
  • 27 Prager GW, Poettler M. Angiogenesis in cancer. Basic mechanisms and therapeutic advances. Hamostaseologie 2012; 32: 105-114.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Cassidy J. et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
    CrossrefPubMedGoogle Scholar
  • 29 Saltz LB. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
    CrossrefPubMedGoogle Scholar
  • 30 Loges S. et al. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167-170.
    CrossrefPubMedGoogle Scholar
  • 31 Malla RR. et al. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther 2011; 18: 419-434.
    CrossrefPubMedGoogle Scholar
  • 32 Alexander RA. et al. VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res 2012; 94: 125-135.
    CrossrefPubMedGoogle Scholar
  • 33 Czekay RP. et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160: 781-791.
    CrossrefPubMedGoogle Scholar
  • 34 Prager GW. et al. Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood 2009; 113: 1383-1390.
    CrossrefPubMedGoogle Scholar
  • 35 Brunner PM. et al. Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells. Blood 2011; 117: 4154-4161.
    CrossrefPubMedGoogle Scholar
  • 36 Schmitt M. et al. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010; 10: 1051-1067.
    CrossrefPubMedGoogle Scholar
  • 37 Buchler P. et al. Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia 2009; 11: 196-206.
    CrossrefPubMedGoogle Scholar
  • 38 Kietzmann T. et al. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999; 94: 4177-4185.
    PubMedGoogle Scholar
  • 39 Paez-Ribes M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
    CrossrefPubMedGoogle Scholar
  • 40 Ebos JM. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
    CrossrefPubMedGoogle Scholar
  • 41 Nozaki S. et al. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy. Anticancer Drugs 2006; 17: 1109-1117.
    CrossrefPubMedGoogle Scholar
  • 42 Kenny HA. et al. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res 2011; 17: 459-471.
    CrossrefPubMedGoogle Scholar